On October 22, 2018 HeatBiologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that Jeff Hutchins, Ph.D. Chief Scientific and Operating Officer, plans to present "The Clinical Effectiveness of an Immuno-oncology Combination Utilizing a Multi-antigen T-cell Activation Platform with Immune Checkpoint Inhibition" at the Precision: Lung Cancer World R&D Summit (Press release, Heat Biologics, OCT 22, 2018, View Source [SID1234530185]). The conference is being held on October 29-30, 2018 at the Wyndam Boston Beacon Hill in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Precision: Lung Cancer World R&D Summit

Date: Monday, October 29, 2018

Time: 3:00 PM (Eastern Time)

About Precision: Lung Cancer World R&D Summit

Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.